Leerink Partners began coverage on shares of Obsidian Therapeutics (NASDAQ:OBX – Free Report) in a research note issued to investors on Tuesday, MarketBeat reports. The firm issued an outperform rating and a $32.00 price target on the stock.
Several other brokerages have also commented on OBX. Piper Sandler began coverage on shares of Obsidian Therapeutics in a report on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price objective for the company. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Wall Street Zen upgraded shares of Obsidian Therapeutics to a “sell” rating in a research report on Saturday, September 19th. TD Cowen began coverage on shares of Obsidian Therapeutics in a research note on Thursday, August 6th. They issued a “buy” rating for the company. Finally, William Blair assumed coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 9th. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $39.00.
View Our Latest Stock Analysis on OBX
Obsidian Therapeutics Price Performance
Obsidian Therapeutics Company Profile
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc is based in CAMBRIDGE, Mass.
See Also
- Five stocks we like better than Obsidian Therapeutics
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
